Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post-Void Residual Urine Volume (PVR) After Removal of Urinary Catheter in Women Following Benign Vaginal Gynecologic Surgery

Effect of Voiding Position (Standing in the Shower vs. Sitting) on Post-Void Residual Urine Volume (PVR) After Removal of Urinary Catheter in Women Following Benign Vaginal Gynecologic Surgery: A Double-Blind Randomized Controlled Trial

The goal of this clinical trial is to learn if voiding in a standing position in the shower, rather than sitting on a toilet, may reduce pain associated with the act of voiding, thereby facilitating micturition and decreasing both post-void residual volume and the risk of subsequent urinary retention in women that underwent benign vaginal surgeries.

Study Overview

• Status: Recruiting
• Conditions: Pain; Urinary Retention; UTI; Post-void Residual Volume; Recatheterization
• Intervention / Treatment: Behavioral: Voiding position - Standing in the shower; Behavioral: Voiding position - Sitting on the toilet

• Study Type: Interventional
• Enrollment (Estimated): 100
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Elad Preuss, M.D; Phone Number: +072545228700; Email: eladp@assuta.co.il

Study Locations

• Israel
  • Ashdod, Israel
    • Recruiting
    • Assuta Ashdod Medical Center
    • Contact: Elad Preuss - M.D
  • Ashdod, Israel
    • Not yet recruiting
    • Assuta Ashdod Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Adult women (≥18 years old).
• Undergoing benign vaginal gynecologic surgery with indwelling catheter during surgery.
• No bladder injury during surgery.
• Ability and willingness to consent.
• No known neurological or urinary conditions affecting voiding.
• No active urinary tract infection at time of catheter removal.

Exclusion Criteria:

• Bladder injury during surgery.
• Neurological disease affecting bladder function.
• Active urinary tract infection.
• Inability to void either standing in shower or sitting (depending on randomization).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Voiding position - Standing in the shower; After removal of urine catheterization, during first micturation, the patient will stand in the shower with the water on her vulvar area	Behavioral: Voiding position - Standing in the shower; After the removal of urine catheter, for the first micturation the woman will stand in the shower with the water on her vulvar area
Other: Voiding position - Sitting on the toilet; After the removal of urine catheter for the first micturation - the patient will sit on the toilet	Behavioral: Voiding position - Sitting on the toilet; After the removal of urine catheter, for the first micturation the women will sit on the toiled

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Post-void residual volume>150 CC	after the first void following catheter removal	The following 7 days after surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Success rate of voiding trial	no need for recatheterization	The following 7 days after surgery
UTI	in the 7 days following the surgery	The following 7 days after surgery
Urinary retention	REST>150 ml	The following 7 days after surgery
Post-void residual volume	in ml	The following 7 days after surgery
Pain during micturition	Pain during micturition, using The Visual Analogue Scale (VAS) 0-10. O means no pain, 10 means worst pain imaginable.	The following 7 days after surgery

Collaborators and Investigators

• Sponsor: Assuta Ashdod Hospital

Study record dates

Study Major Dates

• Study Start (Actual): January 20, 2026
• Primary Completion (Estimated): January 20, 2028
• Study Completion (Estimated): January 20, 2028

Study Registration Dates

• First Submitted: January 4, 2026
• First Submitted That Met QC Criteria: January 20, 2026
• First Posted (Actual): January 28, 2026

Study Record Updates

• Last Update Posted (Actual): March 25, 2026
• Last Update Submitted That Met QC Criteria: March 22, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Neurologic Manifestations; Male Urogenital Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urination Disorders; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Pain; Urinary Retention
• Other Study ID Numbers: AAA-0147-25

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No